# Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects

> **NCT04416126** · PHASE1 · COMPLETED · sponsor: **Arcturus Therapeutics, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Ornithine Transcarbamylase Deficiency

## Interventions

- **BIOLOGICAL:** ARCT-810
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04416126
- **Lead sponsor:** Arcturus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2020-12-09
- **Final completion:** 2020-12-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04416126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04416126, "Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04416126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*